Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Other Working Capital Changes (2017 - 2021)

GT Biopharma (GTBP) has disclosed Other Working Capital Changes for 10 consecutive years, with $23000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Other Working Capital Changes rose 118.7% to $23000.0 in Q3 2021 year-over-year; TTM through Sep 2021 was -$524000.0, a 332.89% decrease, with the full-year FY2025 number at -$377000.0, down 550.0% from a year prior.
  • Other Working Capital Changes was $23000.0 for Q3 2021 at GT Biopharma, up from -$26000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $222000.0 in Q4 2019 to a low of -$276000.0 in Q1 2021.
  • A 4-year average of -$24833.3 and a median of -$500.0 in 2019 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 2200.0% in 2020; the steepest drop was 6250.0% in 2020.
  • GT Biopharma's Other Working Capital Changes stood at $7000.0 in 2017, then skyrocketed by 3071.43% to $222000.0 in 2019, then crashed by 210.36% to -$245000.0 in 2020, then skyrocketed by 109.39% to $23000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Other Working Capital Changes are $23000.0 (Q3 2021), -$26000.0 (Q2 2021), and -$276000.0 (Q1 2021).